LV12939B - Sustained release beadlets containing stavudine - Google Patents

Sustained release beadlets containing stavudine Download PDF

Info

Publication number
LV12939B
LV12939B LVP-02-187A LV020187A LV12939B LV 12939 B LV12939 B LV 12939B LV 020187 A LV020187 A LV 020187A LV 12939 B LV12939 B LV 12939B
Authority
LV
Latvia
Prior art keywords
stavudine
beads
beadlets
medicament
magnesium stearate
Prior art date
Application number
LVP-02-187A
Other languages
English (en)
Latvian (lv)
Inventor
Rober Abramowitz
Denise M O'donoghue
Nemichand B Jain
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV12939B publication Critical patent/LV12939B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
LVP-02-187A 2000-03-30 2002-10-25 Sustained release beadlets containing stavudine LV12939B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19358800P 2000-03-30 2000-03-30

Publications (1)

Publication Number Publication Date
LV12939B true LV12939B (en) 2003-04-20

Family

ID=22714247

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-187A LV12939B (en) 2000-03-30 2002-10-25 Sustained release beadlets containing stavudine

Country Status (26)

Country Link
US (1) US7135465B2 (fr)
EP (1) EP1267879A2 (fr)
JP (1) JP2003528905A (fr)
KR (1) KR20030011805A (fr)
CN (1) CN1187052C (fr)
AR (1) AR027748A1 (fr)
AU (1) AU2001249591A1 (fr)
BG (1) BG107157A (fr)
BR (1) BR0109602A (fr)
CA (1) CA2404687A1 (fr)
CZ (1) CZ20023003A3 (fr)
EE (1) EE200200564A (fr)
GE (1) GEP20043285B (fr)
HU (1) HUP0302631A2 (fr)
IL (1) IL151475A0 (fr)
LT (1) LT5045B (fr)
LV (1) LV12939B (fr)
MX (1) MXPA02009534A (fr)
NO (1) NO20024645D0 (fr)
NZ (1) NZ522250A (fr)
PE (1) PE20011179A1 (fr)
PL (1) PL366089A1 (fr)
RU (1) RU2239435C2 (fr)
SK (1) SK12822002A3 (fr)
WO (1) WO2001074329A2 (fr)
ZA (1) ZA200207760B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2003257425A1 (en) * 2002-06-27 2004-01-19 Cilag Ag Spherical pellet containing a water-soluble active ingredient
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
AU2006259619A1 (en) * 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
AU2006286314A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (fr) 2006-04-03 2007-10-11 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
EP2010162A4 (fr) * 2006-04-03 2013-01-09 Isa Odidi Composition d'administration de médicament
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
CN102319181B (zh) * 2011-09-08 2014-07-16 广东大华农动物保健品股份有限公司 一种微囊型动物药品的包被工艺
US20140271893A1 (en) * 2013-03-15 2014-09-18 Mcneil-Ppc, Inc. Coated phenylephrine particles and use thereof in pharmaceutical formulations
US20170209385A1 (en) * 2014-07-17 2017-07-27 Dow Global Technolgies Llc Ethylcellulose dispersion and film
CN105511174A (zh) * 2016-01-05 2016-04-20 深圳市华星光电技术有限公司 液晶显示面板和显示装置

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671963A (en) 1983-10-28 1987-06-09 Germino Felix J Stearate treated food products
US4670270A (en) 1984-05-07 1987-06-02 Germino Felix J Stearate treated food products
US4940556A (en) 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4978655A (en) * 1986-12-17 1990-12-18 Yale University Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses
GB8707421D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
CA2126441C (fr) 1991-12-30 1999-12-21 David F. Erkoboni Composition de spheronisation a base de cellulose microcristallisee
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5869097A (en) * 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
GB9403449D0 (en) 1994-02-23 1994-04-13 Wellcome Found Therapeutic benzonitriles
EP0749421B1 (fr) 1994-03-07 1999-09-15 Vertex Pharmaceuticals Incorporated Derives de sulfamides en tant qu'inhibiteurs de protease d'aspartyle
US5955485A (en) 1995-02-23 1999-09-21 Janssen Pharmaceutica, N.V. Use of fused benzothiazoles as neuroprotectants
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
BR9612004A (pt) 1995-12-15 1999-12-28 Cryopreservation Thechnologies Composição para criopreservação de orgão e tratamento de infecções virais e bacterianas
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
US5883252A (en) 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
US5766623A (en) 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
US5780055A (en) 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5905068A (en) 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
AU721653B2 (en) 1996-10-25 2000-07-13 Supernus Pharmaceuticals, Inc. Soluble form osmotic dose delivery system
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6136827A (en) 1997-07-25 2000-10-24 Merck & Co., Inc. Cyclic amine modulations of chemokine receptor activity
ES2234139T3 (es) 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9496798A (en) * 1997-09-19 1999-04-05 Shire Laboratories, Inc. Solid solution beadlet
US5904937A (en) 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6013644A (en) 1997-12-12 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
CA2304959A1 (fr) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Composition pharmaceutique antagoniste de ccr5 et contenant un derive d'anilide
US6140349A (en) 1998-02-02 2000-10-31 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
US7122207B2 (en) * 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6093743A (en) 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
BR9911457A (pt) 1998-06-24 2001-12-11 Univ Emory Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
DE60021065T2 (de) 1999-03-31 2006-06-01 UAF Technologies and Research, LLC, Tucson Virus behandlung
US6136835A (en) 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections

Also Published As

Publication number Publication date
BG107157A (en) 2003-06-30
SK12822002A3 (sk) 2003-02-04
NO20024645L (no) 2002-09-27
CN1187052C (zh) 2005-02-02
WO2001074329A2 (fr) 2001-10-11
CA2404687A1 (fr) 2001-10-11
IL151475A0 (en) 2003-04-10
PL366089A1 (en) 2005-01-24
NO20024645D0 (no) 2002-09-27
AR027748A1 (es) 2003-04-09
ZA200207760B (en) 2004-01-30
KR20030011805A (ko) 2003-02-11
LT2002099A (en) 2003-04-25
BR0109602A (pt) 2004-06-29
PE20011179A1 (es) 2001-12-06
LT5045B (lt) 2003-08-25
HUP0302631A2 (hu) 2003-11-28
EE200200564A (et) 2004-06-15
CN1420774A (zh) 2003-05-28
MXPA02009534A (es) 2003-05-14
NZ522250A (en) 2004-09-24
WO2001074329A3 (fr) 2002-05-10
US7135465B2 (en) 2006-11-14
CZ20023003A3 (cs) 2002-11-13
RU2239435C2 (ru) 2004-11-10
JP2003528905A (ja) 2003-09-30
GEP20043285B (en) 2004-07-26
RU2002126540A (ru) 2004-03-27
EP1267879A2 (fr) 2003-01-02
US20020002147A1 (en) 2002-01-03
AU2001249591A1 (en) 2001-10-15

Similar Documents

Publication Publication Date Title
US7135465B2 (en) Sustained release beadlets containing stavudine
EP1123087B1 (fr) Systeme d'administration de medicaments par doses pulsees par voie orale
US5196203A (en) Theophylline dosage form
US4427648A (en) Dipyridamole-containing pharmaceutical form
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
EP0103991A2 (fr) Capsule analgésique
US5277916A (en) Tetracycline dosage form
EP0377517A2 (fr) Forme de dose de théophylline
PL188834B1 (pl) Farmaceutyczne formulacje zawierające tramadol lub jego fizjologicznie akceptowane sole oraz sposóbwytwarzania tych formulacji
JPH01226821A (ja) テトラサイクリンの剤形
AU1506500A (en) Pharmaceutical combination preparations
EP1109535B1 (fr) Acetaminophene a liberation prolongee
AU2004251439A1 (en) Tablet comprising fluvastatin and carmellose calcium
US12042474B2 (en) Lacosamide pharmaceutical composition and dosage form thereof
AU614328B2 (en) Tetracycline dosage form
AU2004200325B2 (en) Oral Pulsed Dose Drug Delivery System
AU2006236052B2 (en) Oral pulsed dose drug delivery system
EP2221049A2 (fr) Composition pharmaceutique solide de didanosine
MXPA06004017A (es) Formas de dosis una vez al dia de trospio